Illumina, Inc. (NASDAQ:ILMN) Director Jay T. Flatley sold 3,300 shares of the business’s stock in a transaction that occurred on Wednesday, November 14th. The shares were sold at an average price of $312.50, for a total value of $1,031,250.00. Following the transaction, the director now owns 376,710 shares of the company’s stock, valued at approximately $117,721,875. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Shares of Illumina stock opened at $319.93 on Monday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 2.24 and a current ratio of 2.46. The firm has a market cap of $47.03 billion, a price-to-earnings ratio of 79.98, a price-to-earnings-growth ratio of 2.37 and a beta of 1.07. Illumina, Inc. has a 1-year low of $207.51 and a 1-year high of $372.61.

Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, October 23rd. The life sciences company reported $1.52 earnings per share for the quarter, beating the consensus estimate of $1.26 by $0.26. The firm had revenue of $853.00 million for the quarter, compared to the consensus estimate of $825.65 million. Illumina had a return on equity of 27.10% and a net margin of 21.09%. The firm’s revenue for the quarter was up 19.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.11 EPS. On average, research analysts forecast that Illumina, Inc. will post 5.75 EPS for the current fiscal year.

A number of institutional investors have recently made changes to their positions in ILMN. Janney Montgomery Scott LLC raised its stake in shares of Illumina by 10.0% in the 2nd quarter. Janney Montgomery Scott LLC now owns 23,555 shares of the life sciences company’s stock worth $6,579,000 after buying an additional 2,141 shares in the last quarter. Standard Life Aberdeen plc raised its stake in shares of Illumina by 31.1% in the 2nd quarter. Standard Life Aberdeen plc now owns 34,546 shares of the life sciences company’s stock worth $9,650,000 after buying an additional 8,199 shares in the last quarter. Waters Parkerson & CO. LLC bought a new stake in shares of Illumina in the 2nd quarter worth $223,000. Bank of Nova Scotia raised its stake in shares of Illumina by 216.4% in the 2nd quarter. Bank of Nova Scotia now owns 59,185 shares of the life sciences company’s stock worth $16,529,000 after buying an additional 40,478 shares in the last quarter. Finally, Eqis Capital Management Inc. raised its stake in shares of Illumina by 40.7% in the 2nd quarter. Eqis Capital Management Inc. now owns 9,676 shares of the life sciences company’s stock worth $2,702,000 after buying an additional 2,797 shares in the last quarter. 90.13% of the stock is currently owned by hedge funds and other institutional investors.

A number of research analysts recently issued reports on ILMN shares. UBS Group started coverage on Illumina in a research report on Tuesday, October 9th. They set a “neutral” rating and a $340.00 price objective for the company. Zacks Investment Research lowered Illumina from a “hold” rating to a “sell” rating in a research report on Tuesday, October 16th. Argus set a $372.00 price objective on Illumina and gave the company a “buy” rating in a research report on Friday, August 10th. Piper Jaffray Companies boosted their price objective on Illumina to $380.00 and gave the company an “overweight” rating in a research report on Tuesday, October 2nd. Finally, BidaskClub lowered Illumina from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 4th. Six equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $330.94.

TRADEMARK VIOLATION NOTICE: “Illumina, Inc. (ILMN) Director Sells $1,031,250.00 in Stock” was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.dailypolitical.com/2018/11/19/illumina-inc-ilmn-director-sells-1031250-00-in-stock.html.

About Illumina

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Featured Article: Compound Interest

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.